| Mindfulness | Interpersonal effectiveness |  |  |  | ||
---|---|---|---|---|---|---|---|
 | (n = 19) | (n = 25) | X 2 /F | t | p | ||
Demographics | |||||||
 Gender n, (% females) | 17 | (90.0) | 24 | (96.0) | .72 |  | .57 |
 Age, M (SD) | 32.95 | (7.48) | 32.00 | (7.49) |  | −.41 | .68 |
 Years of education, M (SD) | 12.44 | (3.97) | 11.41 | (3.20) |  | −.92 | .35 |
 Marital status n, (% not married) | 13 | (68.4) | 12 | (48.0) | 2.53 |  | .28 |
Clinical characteristics | |||||||
 DIB-R total score, M (SD) | 7.71 | (.98) | 8.17 | (1.40) |  | 1.16 | .25 |
 Presence of Axis I co-morbidities, n (%) | |||||||
 - Anxiety Disorders | 17 | (89.5) | 19 | (76.0) | 1.31 |  | .25 |
 - Major Depressive Disorder | 13 | (68.4) | 16 | (64.0) | .09 |  | .75 |
 - Bulimia Nervosa | 12 | (63.2) | 9 | (36.0) | 3.19 |  | .07 |
 - Substance Abuse Disorder | 11 | (57.9) | 20 | (80.0) | 2.53 |  | .11 |
 Other PD diagnosis n, (%) | 9 | (64.3) | 16 | (80.0) | 1.04 |  | .31 |
Pharmacological treatment | Â | Â | Â | Â | Â | Â | Â |
 - SSRI n, (%) | 15 | (78.9) | 14 | (66.7) | .75 |  | .38 |
 - Benzodiazepines n, (%) | 9 | (47.4) | 12 | (57.1) | .38 |  | .53 |
 - Mood stabilizers n, (%) | 2 | (10.5) | 1 | (4.8) | .47 |  | .48 |
 - Antipsychotics n, (%) | 8 | (42.1) | 9 | (42.9) | .00 |  | .96 |